Skip to main content
. 2014 Mar 14;9(3):e92128. doi: 10.1371/journal.pone.0092128

Figure 9. Hesperidin and mangiferin did not alter the expression of A) BAX and B) BCL2 during the 12h treatment.

Figure 9

Top panel: Following 12h treatment of HeLa cells with hesperidin (h) (2.5 μg/ml, 4,01 μM), mangiferin (5 μg/ml, 11.84 μM) (m), and hesperidin (2.5 μg/ml, 4.01 μM) in a presence of mangiferin (5 μg/ml, 11.84 μM) (h+m), the mRNA levels were monitored in real - time PCR experiments. The BAX and BCL2 mRNA levels results from 2 independent experiments (n = 8) are plotted relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 18S rRNA levels and expressed as a fold change over the EtOH control. Error bars represent standard derivations.Bottom panel: Following 12h of treatment of HeLa cells with hesperidin (h) (2.5 μg/ml, 4.01 μM), mangiferin (5 μg/ml, 11.84 μM) (m), and hesperidin (2.5 μg/ml, 4.01 μM) in a presence of mangiferin (5 μg/ml, 11.84 μM) (h+m), the protein levels of Bax and BCL2 were detected with SDS-PAGE and Western Blot and related to beta actin levels. 2 individual samples (3 μg of total protein per lane) were tested for each treatment and the experiments were repeated twice.